This Week in Cardiology — May 14, 2026

Welcome to This Week in Cardiology. This week we're covering 10 notable papers spanning heart failure management, advances in structural and rhythm disorders, and new strategies in prevention. Let's dive in.

Our first theme is the management of acute and chronic heart failure, a topic addressed by three papers this week.

A comprehensive review in the Journal of the American College of Cardiology sets the stage by outlining a modern, integrated pathway for managing acute heart failure, from the emergency department to long-term remission [1]. The authors emphasize a holistic, patient-centered approach to ensure timely recognition and initiation of guideline-directed medical therapies.

Putting this into a real-world context, a study in Heart provides a look at how things have changed over the past decade [9]. Investigators compared two large French surveys of patients hospitalized with acute heart failure, one from 2009 and another from 2021. They found that while patient age and ejection fraction categories remained stable, the burden of comorbidities has increased. The emergency department is increasingly the main entry point for these patients. Despite these challenges, there was a significant decrease in 6-month mortality, which fell from about 25% to 21%. However, the study also highlights a major gap: in patients with HFrEF, the prescription of ACE inhibitors, ARBs, or ARNIs at discharge actually decreased over the 12-year period, from 78% down to 71%. This points to a persistent shortcoming in implementing evidence-based therapies.

One therapy that is gaining traction is addressed in the Journal of the American Heart Association [4]. This study focused specifically on older patients, a group often underrepresented in major trials. Using data from the Get with the Guidelines-Heart Failure registry in the United States, researchers analyzed nearly 9,000 Medicare beneficiaries aged 65 or older who were hospitalized for HFrEF. Of these, only 16.5% were started on an SGLT2 inhibitor by discharge. After statistical adjustment, initiating an SGLT2 inhibitor was associated with a 24% lower risk of all-cause mortality over one year. It was also linked to an 11% lower risk of all-cause readmission and a 16% lower risk of heart failure readmission. These benefits were consistent across all subgroups, including the very elderly and those with or without diabetes. The findings provide strong, real-world support for initiating SGLT2 inhibitors in older, hospitalized HFrEF patients to improve post-discharge outcomes.

Next, we turn to structural heart disease and cardiac pacing.

First, a study in the Journal of the American Heart Association tackles a key question in valvular heart disease: surgical versus transcatheter aortic valve replacement for patients with bicuspid aortic stenosis [5]. Bicuspid anatomy is often an exclusion criterion in major TAVR trials, leaving a gap in the evidence.

The Study

This was a multicenter, observational study using propensity score matching to compare outcomes. After matching, the analysis included 256 pairs of patients with a median age of 75.

Results

At one year, the primary composite outcome of all-cause mortality, stroke, rehospitalization, or valve dysfunction was not significantly different between the TAVR and SAVR groups, occurring in 15% and 12% of patients, respectively. However, when looking at individual components and extending follow-up to two years, a different picture emerged. The risk of stroke was three times higher in the TAVR group, and the risk of valve dysfunction was four times higher. Both of these differences were statistically significant at the two-year mark.

Conclusions

While 1-year composite outcomes were similar, the emerging signals of higher stroke and valve dysfunction risk with TAVR in this bicuspid population underscore the need for randomized controlled trials to define the optimal strategy. For now, it suggests that surgery may remain the preferred option for many of these patients, and careful shared decision-making is critical.

Staying on the topic of hardware, a primer in the journal Heart reviews the paradigm shift in cardiac pacing towards conduction system pacing [8]. This includes both His bundle pacing and left bundle branch area pacing. The authors remind us that while traditional right ventricular pacing is reliable, it creates dyssynchronous activation that can lead to pacing-induced cardiomyopathy and atrial fibrillation. Conduction system pacing attempts to avoid this by recruiting the intrinsic His-Purkinje network, restoring a more physiologic, synchronized contraction. The review serves as a practical guide for general cardiologists on the rationale, techniques, and clinical evidence supporting this evolving field, which is becoming increasingly important for patients with bradycardia and for some requiring cardiac resynchronization therapy.

Our third theme covers new approaches in arrhythmia management and risk stratification.

First, can we safely manage low-risk atrial fibrillation outside of the hospital? A pilot study from Australia, published in Heart, explored this very question [2]. The STAY study developed a community-based model of care where paramedics identified low-risk patients with acute AF. After cardiologist confirmation, patients were treated on scene with metoprolol or rivaroxaban and then transitioned to virtual care or a rapid-access AF clinic, completely bypassing the emergency department. Of 573 patients assessed, nearly 80% were deemed low-risk and suitable for this pathway. Among the 57 patients recruited into the pilot, there were no deaths at 30 days, and only 3 patients, or 5%, required hospital admission. The average time to specialist care was just over one day. This pilot suggests that for a selected, low-risk AF population, a community-based pathway is feasible and safe, and could significantly reduce the burden on emergency services. Further assessment at scale is now needed.

From a common arrhythmia to a rare one, a paper in Cardiovascular Research explores a futuristic approach to risk stratification in Long QT syndrome [3]. Current methods for predicting which genetic variants confer the highest risk of cardiac events are insufficient. In this study, researchers used human induced pluripotent stem cells to grow patient-specific cardiomyocytes carrying six different pathogenic variants in the KCNQ1 or KCNH2 genes. They then recorded detailed electrophysiological data from these cells and used it to train a machine learning model. The model was able to classify the risk level associated with each genetic variant with 89% accuracy. This proof-of-concept study demonstrates that combining stem cell technology with machine learning could provide a powerful new tool for granular, variant-specific risk stratification, potentially leading to more personalized management for patients with inherited arrhythmic disorders.

Finally, we'll cover prevention, disparities, and special populations.

In the realm of secondary prevention, the VICTORION-INCEPTION trial, published in the Journal of the American Heart Association, evaluated the LDL-lowering efficacy of inclisiran in patients with a recent acute coronary syndrome [6]. This open-label trial randomized 400 patients with an LDL-C of 70 mg/dL or higher to receive inclisiran plus usual care, or usual care alone. The results were striking. By day 330, two-thirds of patients in the inclisiran group achieved an LDL-C below 70, compared to just 28% in the usual care group. Furthermore, 54% of the inclisiran group reached the more aggressive target of below 55, versus only about 14% with usual care. This represented a nearly 47% greater reduction in LDL-C for the inclisiran group. The therapy was well tolerated. This is the first trial of inclisiran in the post-ACS setting and shows that early initiation leads to rapid and sustained attainment of guideline-directed LDL goals.

Next, another paper in the Journal of the American Heart Association provides a sobering look at gender representation in the trials that form the basis of our clinical guidelines [7]. Investigators performed a systematic review of over 1,600 studies referenced in the American College of Cardiology and American Heart Association guidelines for chronic coronary artery disease, chest pain, and revascularization. They found a persistent underrepresentation of women across the board. Women made up only about 30% of participants in revascularization trials and 33% in chronic coronary disease trials. The study's participation-to-prevalence ratios, which compare enrollment to disease burden, confirmed substantial gaps. Despite four decades of advocacy, overall progress has been minimal. The paper is a critical reminder that our evidence base is not as generalizable as we might think and that proactive strategies are urgently needed to ensure equitable research.

Lastly, a review in the European Heart Journal draws attention to the converging fields of cardiology and oncology [10]. The article highlights the shared challenges and growing burden of patients who have both cancer and cardiovascular disease. As cancer therapies improve and patients live longer, cardiovascular complications are becoming more prevalent. This serves as an important prompt for all cardiologists to be aware of the principles of cardio-oncology and the importance of multidisciplinary collaboration to manage these complex patients.

If you only have time for one paper this week, make it the study on SGLT2 inhibitors in older, hospitalized HFrEF patients from the Journal of the American Heart Association [4]. It provides strong, real-world evidence from United States clinical practice that initiating these agents at discharge saves lives and prevents readmissions in a common, high-risk population we see every day.

Here are the key takeaways from this week in Cardiology.

First: For older patients hospitalized with heart failure with reduced ejection fraction, in-hospital initiation of SGLT2 inhibitors is associated with a significant reduction in one-year mortality and readmissions. This real-world evidence strongly supports making this a routine part of discharge care.

Second: In patients with bicuspid aortic stenosis, TAVR appears to have similar composite outcomes to surgical replacement at one year, but emerging data suggests a higher risk of stroke and valve dysfunction at two years. This highlights the need for caution and reinforces the importance of shared decision-making and ongoing randomized trials.

Third: For secondary prevention after an acute coronary syndrome, early initiation of inclisiran is highly effective at achieving and maintaining guideline-recommended LDL cholesterol goals, suggesting a more aggressive lipid-lowering strategy is feasible and effective in this high-risk group.

Fourth: Despite overall improvements in heart failure mortality, significant gaps persist in the implementation of guideline-directed medical therapy at discharge. And in a broader context, women remain persistently underrepresented in the major ischemic heart disease trials that inform our clinical guidelines, a disparity that requires urgent action.

That's your roundup for This Week in Cardiology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.